Our Pricing

Clinical Guidance on Promethazine BNF Applications

Understanding promethazine BNF guidance UK is essential for safe, effective use of this first-generation antihistamine. At Cured Pharmacy, our UK-registered clinical team applies current BNF protocols to assess every promethazine prescription, ensuring appropriate dosing and patient suitability before dispensing Phenergan products from £17.54.

Promethazine BNF Classification and Mechanism

The British National Formulary classifies promethazine hydrochloride as a sedating antihistamine with antimuscarinic and sedative properties [1]. Unlike non-sedating second-generation antihistamines, promethazine readily crosses the blood-brain barrier, producing central nervous system depression that underlies both its therapeutic effects and side effect profile.

Promethazine competitively antagonises histamine at H1 receptors, preventing histamine-mediated vasodilation, increased vascular permeability, and pruritus [1]. Its anticholinergic activity contributes to antiemetic effects by blocking muscarinic receptors in the vomiting centre and vestibular apparatus, making it particularly effective for motion sickness and nausea associated with vestibular disorders [2].

BNF-Approved Indications for Promethazine

The BNF lists three primary indications for promethazine: symptomatic relief of allergy (including hay fever and urticaria), short-term management of insomnia, and prevention and treatment of nausea and vomiting [1]. Each indication requires specific dosing adjustments and duration limits to minimise adverse effects.

For allergic conditions, promethazine provides rapid symptom control but should not exceed 10 consecutive days without medical review due to tolerance development and anticholinergic burden [3]. In sleep disturbance, BNF guidance restricts use to 7 days maximum, as longer-term administration increases daytime sedation, cognitive impairment, and paradoxical insomnia upon withdrawal.

Motion Sickness and Vestibular Disorders

Promethazine demonstrates particular efficacy in motion sickness when administered 1-2 hours before travel, with effects lasting 12-24 hours [2]. The BNF recommends a single 25mg dose the night before travel, followed by 25mg on the morning of departure for optimal prophylaxis. For established nausea, the same dose may be repeated after 6-8 hours if needed, though patients should be warned about profound sedation that impairs driving ability.

Promethazine BNF Dosing Protocols

BNF dosing for promethazine varies significantly by indication and patient age. For adults with allergic conditions, the standard dose is 25mg at night, or 10-20mg two to three times daily if daytime administration is necessary [1]. This flexible regimen allows tailoring to symptom severity whilst minimising daytime impairment in working patients.

For insomnia, the BNF specifies 25mg taken 30-60 minutes before bedtime in adults, with a maximum duration of 7 consecutive nights [1]. Elderly patients require dose reduction to 10-20mg due to increased sensitivity to anticholinergic effects and prolonged elimination half-life, which averages 16 hours in older adults compared to 12 hours in younger populations [3].

Paediatric Dosing Considerations

The BNF strictly contraindicates promethazine in children under 2 years due to fatal respiratory depression risk [1]. For children aged 2-5 years, maximum dose is 5-15mg daily in divided doses for allergy only; sleep and antiemetic use remain contraindicated in this age group. Children 5-10 years may receive 10-25mg daily for allergy or nausea, whilst those over 10 years follow adult dosing with appropriate weight-based adjustments.

Contraindications and Drug Interactions

The BNF lists absolute contraindications including children under 2 years, concurrent monoamine oxidase inhibitor therapy, and acute porphyria [1]. Relative contraindications encompass prostatic hypertrophy, urinary retention, angle-closure glaucoma, pyloric stenosis, and severe coronary artery disease where anticholinergic effects may precipitate complications.

Promethazine potentiates central nervous system depressants including alcohol, benzodiazepines, opioids, and other sedating antihistamines, increasing fall risk and respiratory depression [2]. Concurrent use with antimuscarinic drugs (tricyclic antidepressants, antiparkinson agents, antispasmodics) intensifies anticholinergic burden, manifesting as confusion, urinary retention, constipation, and heat intolerance particularly in elderly patients [3].

Adverse Effects and Safety Monitoring

The most frequent adverse effects reflect promethazine's anticholinergic and sedative properties: drowsiness (affecting up to 70% of users), dry mouth, blurred vision, urinary retention, and constipation [1]. Paradoxical stimulation occurs in approximately 5-10% of children and occasionally in adults, presenting as restlessness, insomnia, tremor, and irritability requiring immediate discontinuation [3].

Rare but serious adverse effects include blood dyscrasias (agranulocytosis, thrombocytopenia), photosensitivity reactions, and neuroleptic malignant syndrome when used in high doses [1]. Patients should be counselled to report fever, sore throat, unusual bruising, or severe skin reactions immediately. Long-term use beyond BNF-recommended durations increases risk of cognitive impairment and anticholinergic dementia, particularly in patients over 65 years.

Driving and Skilled Tasks

The BNF mandates clear counselling that promethazine impairs psychomotor performance, with sedative effects persisting 12-24 hours after a single dose [1]. Patients must avoid driving, operating machinery, or performing tasks requiring alertness until they know how promethazine affects them individually. Alcohol consumption amplifies impairment exponentially and should be avoided during treatment.

Clinical Assessment at Cured Pharmacy

Every promethazine prescription at Cured Pharmacy undergoes assessment by our UK-registered clinical team following BNF protocols. Our online consultation captures essential information including current medications (to identify interactions), existing medical conditions (particularly glaucoma, prostate enlargement, epilepsy), and treatment duration to ensure appropriate prescribing within BNF guidelines.

Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees clinical governance, ensuring all promethazine prescriptions align with MHRA licensing and NICE guidance. We stock Phenergan 25mg Tablets from £17.54, Phenergan Elixir from £17.54 for patients unable to swallow tablets, and Phenergan Night Tablets 25mg from £17.54 for short-term insomnia management. All products are UK-licensed, stored in our GPhC-registered facility (9012511), and dispensed with comprehensive patient information leaflets detailing BNF-compliant usage.

Scientific References

1. Joint Formulary Committee. (2024). British National Formulary (BNF) 87. London: BMJ Group and Pharmaceutical Press. https://bnf.nice.org.uk/drugs/promethazine-hydrochloride/
2. Simons, F. E. R., & Simons, K. J. (2011). Histamine and H1-antihistamines: celebrating a century of progress. Journal of Allergy and Clinical Immunology, 128(6), 1139-1150.e4. https://doi.org/10.1016/j.jaci.2011.09.005
3. Gray, S. L., Anderson, M. L., Dublin, S., Hanlon, J. T., Hubbard, R., Walker, R., ... & Larson, E. B. (2015). Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Internal Medicine, 175(3), 401-407. https://doi.org/10.1001/jamainternmed.2014.7663

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.